amg 876
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01492465)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor 21Supplementation
FGF21 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- amg 876
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03976401 | Phase 2 | May 28, 2019 | Akero Therapeutics, Inc |
| NCT01856881 | Phase 1 | Mar 1, 2013 | Amgen |
| NCT01492465 | Phase 1 | Nov 1, 2011 | Amgen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 2 | 2 | 1 | 2011 |
| Akero Therapeutics, Inc | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1